Comparative Pharmacology
Head-to-head clinical analysis: PARAFLEX versus ROBAXIN 750.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARAFLEX versus ROBAXIN 750.
PARAFLEX vs ROBAXIN-750
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Centrally acting muscle relaxant; inhibits polysynaptic reflexes at the spinal cord level, possibly by depressing the central nervous system.
Methocarbamol, the active ingredient in Robaxin-750, is a centrally acting muscle relaxant. Its precise mechanism is not fully understood, but it is believed to cause general central nervous system depression, possibly through inhibition of polysynaptic reflexes at the spinal cord level.
250-500 mg orally once daily, may increase to 500 mg twice daily if needed. Maximum 500 mg/day.
750 mg orally four times daily (total daily dose 3000 mg).
None Documented
None Documented
Terminal elimination half-life is approximately 2–3 hours, allowing for multiple daily dosing.
Terminal elimination half-life: 1-2 hours (methocarbamol); clinical context: short half-life necessitates frequent dosing (q6h) and may lead to fluctuating plasma levels.
Renal excretion of unchanged drug and metabolites accounts for approximately 50% of an oral dose; fecal excretion accounts for about 20%.
Renal: 90-95% as metabolites (mainly conjugated), <1% unchanged; biliary/fecal: minor; <2% eliminated in feces.
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant